New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare blood pressure lowering effect of azilsartan with that of valsartan in Japanese patients with hypertension who have already taken normal-dose angiotensin II receptor blockers.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nara Medical University
• Treatments: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Azilsartan medoxomil; Valsartan

Criteria

Inclusion Criteria:

• Hypertensive patients treated with normal-dose angiotensin II receptor blockers (ARBs) in Japan

• Normal-dose ARBs in Japan are defined as follows: losartan potassium 50 mg, candesartan cilexetil 8 mg, valsartan 80 mg, telmisartan 40 mg, olmesartan medoxomil 20 mg, or irbesartan 100mg per day.

Exclusion Criteria:

• Hypersensitivity for azilsartan and valsartan

• Pregnant female

• History of azilsartan use within 3 months